{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:59:36Z","timestamp":1787497176638,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research and Development Fund of Peking University People's Hospital","award":["teaching programme, NO. RDE 2021-17"],"award-info":[{"award-number":["teaching programme, NO. RDE 2021-17"]}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["No. Z-2018-40-2101"],"award-info":[{"award-number":["No. Z-2018-40-2101"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7192211"],"award-info":[{"award-number":["7192211"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The central nervous system (CNS) is considered as one of the most frequently affected organs in antiphospholipid syndrome (APS). This study investigated the prevalence of CNS manifestations in APS and associated risk factors and evaluated stroke recurrence. We carried out this retrospective study from 2009 to 2021 at Peking University People\u2019s Hospital, which enrolled 342 APS patients, and 174 neurologic events were suffered by 119 patients (34.8%). Patients with and without CNS involvement were compared regarding demographics and laboratory parameters. The analysis showed that older age, livedo reticularis, and dyslipidaemia were significant related factors for CNS manifestations (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.047, 0.038, and 0.030 respectively). The use of anticoagulants (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004), and\/or hydroxychloroquine (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.016) appeared to associated with a lower incidence of CNS manifestations. During a median follow-up of 4.1\u00a0years, 10 individuals developed new episodes of stroke in APS patients with previous ischemic strokes. Livedo reticularis, smoking and male gender may predict the risk of recurrent stroke (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.020, 0.006, and 0.026 respectively). Collectively, our results indicated the protective and risk factors for CNS manifestations, as well as demonstrated that APS patients appeared at high risk of stroke recurrence despite current therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35955-2","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:02:51Z","timestamp":1685606571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome"],"prefix":"10.1038","volume":"13","author":[{"given":"Meige","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"2","key":"35955_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295\u2013306 (2006).","journal-title":"J. Thromb. Haemost."},{"issue":"1\u20132","key":"35955_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2007.11.011","volume":"30","author":"Y Shoenfeld","year":"2008","unstructured":"Shoenfeld, Y., Twig, G., Katz, U. & Sherer, Y. Autoantibody explosion in antiphospholipid syndrome. J. Autoimmun. 30(1\u20132), 74\u201383 (2008).","journal-title":"J. Autoimmun."},{"issue":"8","key":"35955_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11910-021-01124-z","volume":"21","author":"M Leal-Rato","year":"2021","unstructured":"Leal-Rato, M., Bandeira, M., Rom\u00e3o, V. C. & Aguiar-de-Sousa, D. Neurologic manifestations of the antiphospholipid syndrome\u2014an update. Curr. Neurol. Neurosci. Rep. 21(8), 41 (2021).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6","key":"35955_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2014","unstructured":"Cervera, R. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74(6), 1011\u20131018 (2014).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"35955_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/ard.2008.093179","volume":"68","author":"R Cervera","year":"2009","unstructured":"Cervera, R. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 68(9), 1428\u20131432 (2009).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"35955_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera, R. et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthrit. Rheum. 46(4), 1019\u20131027 (2002).","journal-title":"Arthrit. Rheum."},{"issue":"3","key":"35955_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10067-017-3549-1","volume":"36","author":"H Shi","year":"2017","unstructured":"Shi, H. et al. Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: Comparison with Euro-Phospholipid cohort. Clin. Rheumatol. 36(3), 599\u2013608 (2017).","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"35955_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/rheumatology\/key437","volume":"58","author":"F Grimaud","year":"2019","unstructured":"Grimaud, F. et al. Clinical and immunological features of antiphospholipid syndrome in the elderly: A retrospective national multicentre study. Rheumatol. (Oxf.) 58(6), 1006\u20131010 (2019).","journal-title":"Rheumatol. (Oxf.)"},{"issue":"2","key":"35955_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ene.13499","volume":"25","author":"M Radin","year":"2018","unstructured":"Radin, M. et al. The risk of ischaemic stroke in primary antiphospholipid syndrome patients: A prospective study. Eur. J. Neurol. 25(2), 320\u2013325 (2018).","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"35955_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/0961203307081847","volume":"16","author":"AW de Souza","year":"2007","unstructured":"de Souza, A. W. et al. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus 16(10), 782\u2013787 (2007).","journal-title":"Lupus"},{"issue":"5","key":"35955_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/0961203317751065","volume":"27","author":"L Stojanovich","year":"2018","unstructured":"Stojanovich, L., Djokovic, A., Stanisavljevic, N. & Zdravkovic, M. The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome. Lupus 27(5), 858\u2013863 (2018).","journal-title":"Lupus"},{"key":"35955_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-510X(02)00271-X","volume":"203\u2013204","author":"J Chapman","year":"2002","unstructured":"Chapman, J. et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 203\u2013204, 81\u201384 (2002).","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"35955_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1017\/S2045796017000683","volume":"27","author":"Y Faiad","year":"2018","unstructured":"Faiad, Y. Frequency of use of the International Classification of Diseases ICD-10 diagnostic categories for mental and behavioural disorders across world regions. Epidemiol. Psychiatr. Sci. 27(6), 568\u2013576 (2018).","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"5","key":"35955_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","volume":"17","author":"J Olesen","year":"2018","unstructured":"Olesen, J. International classification of headache disorders. Lancet Neurol. 17(5), 396\u2013397 (2018).","journal-title":"Lancet Neurol."},{"issue":"9","key":"35955_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1177\/0961203318776110","volume":"27","author":"IF Ricarte","year":"2018","unstructured":"Ricarte, I. F. et al. Neurologic manifestations of antiphospholipid syndrome. Lupus 27(9), 1404\u20131414 (2018).","journal-title":"Lupus"},{"issue":"6","key":"35955_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/CM9.0000000000001964","volume":"135","author":"C Li","year":"2022","unstructured":"Li, C. et al. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients. Chin. Med. J. (Engl.) 135(6), 658\u2013664 (2022).","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"1","key":"35955_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13317-020-00131-3","volume":"11","author":"I Volkov","year":"2020","unstructured":"Volkov, I. et al. Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun. Highlight. 11(1), 8 (2020).","journal-title":"Auto Immun. Highlight."},{"issue":"2","key":"35955_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12016-021-08862-5","volume":"62","author":"RD Pablo","year":"2022","unstructured":"Pablo, R. D. et al. Risk factors for the development of the disease in antiphospholipid antibodies carriers: A long-term follow-up study. Clin. Rev. Allergy Immunol. 62(2), 354\u2013362 (2022).","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"11","key":"35955_CR19","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/01.STR.29.11.2245","volume":"29","author":"P Verro","year":"1998","unstructured":"Verro, P., Levine, S. R. & Tietjen, G. E. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 29(11), 2245\u20132253 (1998).","journal-title":"Stroke"},{"issue":"8","key":"35955_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1212\/WNL.40.8.1181","volume":"40","author":"SR Levine","year":"1990","unstructured":"Levine, S. R., Deegan, M. J., Futrell, N. & Welch, K. M. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40(8), 1181\u20131189 (1990).","journal-title":"Neurology"},{"issue":"4","key":"35955_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/0961203321990100","volume":"30","author":"M Gomez-Flores","year":"2021","unstructured":"Gomez-Flores, M. et al. Cutaneous manifestations of antiphospholipid syndrome. Lupus 30(4), 541\u2013548 (2021).","journal-title":"Lupus"},{"issue":"2","key":"35955_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/jaut.2000.0409","volume":"15","author":"M Petri","year":"2000","unstructured":"Petri, M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun. 15(2), 145\u2013151 (2000).","journal-title":"J. Autoimmun."},{"issue":"4","key":"35955_CR23","first-page":"499","volume":"23","author":"E Toubi","year":"2005","unstructured":"Toubi, E. et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin. Exp. Rheumatol. 23(4), 499\u2013504 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"35955_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2133.1965.tb14628.x","volume":"77","author":"IB Sneddon","year":"1965","unstructured":"Sneddon, I. B. Cerebrovascular lesions and livedo reticularis. Br. J. Dermatol. 77, 180\u2013185 (1965).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"35955_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00005792-199907000-00001","volume":"78","author":"C Franc\u00e8s","year":"1999","unstructured":"Franc\u00e8s, C. et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Med. (Baltim.) 78(4), 209\u2013219 (1999).","journal-title":"Med. (Baltim.)"},{"issue":"3","key":"35955_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1161\/01.STR.26.3.492","volume":"26","author":"RL Boortz-Marx","year":"1995","unstructured":"Boortz-Marx, R. L., Clark, H. B., Taylor, S., Wesa, K. M. & Anderson, D. C. Sneddon\u2019s syndrome with granulomatous leptomeningeal infiltration. Stroke 26(3), 492\u2013495 (1995).","journal-title":"Stroke"},{"issue":"7","key":"35955_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1212\/01.WNL.0000055931.66009.D3","volume":"60","author":"DA Hilton","year":"2003","unstructured":"Hilton, D. A. & Footitt, D. Neuropathological findings in Sneddon\u2019s syndrome. Neurology 60(7), 1181\u20131182 (2003).","journal-title":"Neurology"},{"issue":"4","key":"35955_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/practneurol-2015-001341","volume":"16","author":"Z Rutter-Locher","year":"2016","unstructured":"Rutter-Locher, Z. et al. Sneddon\u2019s syndrome: It is all in the ectoderm. Pract Neurol. 16(4), 300\u2013303 (2016).","journal-title":"Pract Neurol."},{"issue":"1","key":"35955_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000189506","volume":"75","author":"F Mac\u00e1rio","year":"1997","unstructured":"Mac\u00e1rio, F. et al. Sneddon\u2019s syndrome: A vascular systemic disease with kidney involvement?. Nephron 75(1), 94\u201397 (1997).","journal-title":"Nephron"},{"issue":"2","key":"35955_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0961203310395803","volume":"20","author":"G Ruiz-Irastorza","year":"2011","unstructured":"Ruiz-Irastorza, G. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20(2), 206\u2013218 (2011).","journal-title":"Lupus"},{"issue":"3","key":"35955_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/jcm11030735","volume":"11","author":"NR Tumian","year":"2022","unstructured":"Tumian, N. R. & Hunt, B. J. Clinical management of thrombotic antiphospholipid syndrome. J. Clin. Med. 11(3), 735 (2022).","journal-title":"J. Clin. Med."},{"issue":"11","key":"35955_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1177\/096120330101001103","volume":"10","author":"GR Hughes","year":"2001","unstructured":"Hughes, G. R., Cuadrado, M. J., Khamashta, M. A. & Sanna, G. Headache and memory loss: Rapid response to heparin in the antiphospholipid syndrome. Lupus 10(11), 778 (2001).","journal-title":"Lupus"},{"issue":"928","key":"35955_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/pmj.79.928.81","volume":"79","author":"GR Hughes","year":"2003","unstructured":"Hughes, G. R. Migraine, memory loss, and \u201cmultiple sclerosis\u201d. Neurological features of the antiphospholipid (Hughes\u2019) syndrome. Postgrad. Med. J. 79(928), 81\u201383 (2003).","journal-title":"Postgrad. Med. J."},{"issue":"4","key":"35955_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0961203320983913","volume":"30","author":"JR Schofield","year":"2021","unstructured":"Schofield, J. R., Hughes, H. N., Birlea, M. & Hassell, K. L. A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients. Lupus 30(4), 568\u2013577 (2021).","journal-title":"Lupus"},{"issue":"12","key":"35955_CR35","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","volume":"96","author":"MH Edwards","year":"1997","unstructured":"Edwards, M. H. et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96(12), 4380\u20134384 (1997).","journal-title":"Circulation"},{"issue":"3","key":"35955_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0037-1613033","volume":"87","author":"RG Espinola","year":"2002","unstructured":"Espinola, R. G., Pierangeli, S. S., Gharavi, A. E. & Harris, E. N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 87(3), 518\u2013522 (2002).","journal-title":"Thromb. Haemost."},{"issue":"5","key":"35955_CR37","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"JH Rand","year":"2008","unstructured":"Rand, J. H. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112(5), 1687\u20131695 (2008).","journal-title":"Blood"},{"issue":"10","key":"35955_CR38","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/jth.12363","volume":"11","author":"A Schmidt-Tanguy","year":"2013","unstructured":"Schmidt-Tanguy, A. et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J. Thromb. Haemost. 11(10), 1927\u20131929 (2013).","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"35955_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","volume":"65","author":"E Nuri","year":"2017","unstructured":"Nuri, E. et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65(1), 17\u201324 (2017).","journal-title":"Immunol. Res."},{"issue":"4","key":"35955_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102491","volume":"19","author":"E Kravvariti","year":"2020","unstructured":"Kravvariti, E., Koutsogianni, A., Samoli, E., Sfikakis, P. P. & Tektonidou, M. G. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun. Rev. 19(4), 102491 (2020).","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"35955_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3899\/jrheum.120157","volume":"40","author":"A Broder","year":"2013","unstructured":"Broder, A. & Putterman, C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus. J. Rheumatol. 40(1), 30\u201333 (2013).","journal-title":"J. Rheumatol."},{"issue":"4","key":"35955_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11926-016-0566-z","volume":"18","author":"D Andrade","year":"2016","unstructured":"Andrade, D. & Tektonidou, M. Emerging therapies in antiphospholipid syndrome. Curr. Rheumatol. Rep. 18(4), 22 (2016).","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"35955_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","volume":"42","author":"I Ben-Zvi","year":"2012","unstructured":"Ben-Zvi, I., Kivity, S., Langevitz, P. & Shoenfeld, Y. Hydroxychloroquine: From malaria to autoimmunity. Clin. Rev. Allergy Immunol. 42(2), 145\u2013153 (2012).","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"8","key":"35955_CR44","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/j.1538-7836.2005.01359.x","volume":"3","author":"PG de Groot","year":"2005","unstructured":"de Groot, P. G. & Derksen, R. H. Pathophysiology of the antiphospholipid syndrome. J. Thromb. Haemost. 3(8), 1854\u20131860 (2005).","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"35955_CR45","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78(10), 1296\u20131304 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"35955_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","volume":"42","author":"KL Furie","year":"2011","unstructured":"Furie, K. L. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the american heart association\/american stroke association. Stroke 42(1), 227\u2013276 (2011).","journal-title":"Stroke"},{"issue":"6","key":"35955_CR47","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.thromres.2015.10.029","volume":"136","author":"S Saraiva-Sda","year":"2015","unstructured":"Saraiva-Sda, S. et al. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thromb. Res. 136(6), 1174\u20131178 (2015).","journal-title":"Thromb. Res."},{"issue":"10","key":"35955_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/0961203309106832","volume":"18","author":"R Cervera","year":"2009","unstructured":"Cervera, R., Boffa, M. C., Khamashta, M. A. & Hughes, G. R. The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus 18(10), 889\u2013893 (2009).","journal-title":"Lupus"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35955-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:09:48Z","timestamp":1685610588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35955-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35955"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35955-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"9 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8915"}}